Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

Seroprevalence

There are no seroprevalence terms in the subcorpus

    displaying 1 - 1 records in total 1
    records per page




    Hypokalemia HP Hypokalemia MESHD and Clinical Implications in Patients with Coronavirus Disease MESHD 2019 (COVID-19)

    Authors: dong chen Jr.; Xiaokuni Li; qifa song Sr.; Chenchan Hu Jr.; Feifei Su; Jianyi Dai

    doi:10.1101/2020.02.27.20028530 Date: 2020-02-29 Source: medRxiv

    BACKGROUND: SARS-CoV-2 has caused a series of COVID-19 globally. SARS-CoV-2 binds angiotensin I converting enzyme 2 (ACE2) of renin-angiotensin system (RAS) and causes prevalent hypokalemia HP hypokalemia MESHD METHODS: The patients with COVID-19 were classified into severe hypokalemia HP hypokalemia MESHD, hypokalemia HP hypokalemia MESHD, and normokalemia group. The study aimed to determine the relationship between hypokalemia HP hypokalemia MESHD and clinical features, the underlying causes and clinical implications of hypokalemia HP hypokalemia MESHD. RESULTS: By Feb 15, 2020, 175 patients with COVID-19 (92 women and 83 men; median age TRANS, 46 [IQR, 34-54] years) were admitted to hospital in Wenzhou, China, consisting 39 severe hypokalemia HP hypokalemia MESHD-, 69 hypokalemia HP hypokalemia MESHD-, and 67 normokalemia patients. Gastrointestinal symptoms were not associated with hypokalemia HP hypokalemia MESHD among 108 hypokalemia HP hypokalemia MESHD patients (P>0.05). Body temperature, CK, CK-MB, LDH, and CRP were significantly associated with the severity of hypokalemia HP hypokalemia MESHD (P<0.01). 93% of severe and critically ill MESHD patients had hypokalemia HP hypokalemia MESHD which was most common among elevated CK, CK-MB, LDH, and CRP. Urine K+ loss was the primary cause of hypokalemia HP hypokalemia MESHD. severe hypokalemia HP hypokalemia MESHD patients was given 3 g/day, adding up to an average of 34 (SD=4) g potassium during hospital stay. The exciting finding was that patients responded well to K+ supplements when they were inclined to recovery. CONCLUSIONS: Hypokalemia HP Hypokalemia MESHD is prevailing in patients with COVID-19. The correction of hypokalemia HP hypokalemia MESHD is challenging because of continuous renal K+ loss resulting from the degradation of ACE2. The end of urine K+ loss indicates a good prognosis and may be a reliable, in-time, and sensitive biomarker directly reflecting the end of adverse effect on RAS system.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.